

Pembrolizumab KEYNOTE-24

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE




ADJUSTMENTS


Quality of life



Serious and disabling adverse effects



Other adjustments



Pembrolizumab KEYNOTE-24

SCORE

CURATIVE




Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Thoracic Malignancies  
 Therapeutic Indication: First line treatment of mNSCLC with tumour PD-L1 expression  $\geq 50\%$  TPS with no EGFR or ALK positive tumour mutations  
 Experimental Arm: Pembrolizumab  
 Control Arm: Platinum-based chemotherapy



